

Clinical Trial Information System (CTIS) Bitesize talk

Notifications (session II)

Presented by Noemie Manent and Charalampos Drosos on 23 November 2022 European Medicines Agency



© European Medicines Agency, 2022

Reproduction and/or distribution of the content of these training materials for non-commercial or commercial purposes is authorised, provided the European Medicines Agency is acknowledged as the source of the materials.

The European Medicines Agency developed this training material to enhance public access to information on the Clinical Trial Information System (CTIS). This material describes a preliminary version of CTIS and may therefore not entirely describe the system as it is at the time of use of this material. The Agency does not warrant or accept any liability in relation to the use (in part or in whole) or the interpretation of the information contained in this training material by third parties.



CTIS Bitesize talk:

Notifications (session II)

14:30 - 14:35 **Introduction**

14:35 – 15:55 **CTIS Demonstration Sessions followed by live Q&A Sessions**

15:55 – 16:00 Closing remarks

For questions, go to **www.sli.do** & use event code **#bt23nov**



A few housekeeping rules

For your questions, go to www.sli.do	Or scan slido OR code:	
& use event code #bt23nov	QR code:	

Tips for optimal screen viewing



Make use of the instructions under the embedded video in the event page and connect directly to the IBM channel for the full-screen experience

Increase the video quality from the HD button on the right bottom of the screen setting it to 720p (or 1080p).

Have a stable internet connection



Main Session: Notifications (session II)

Notifications (session II)

• Live demo with Q&A









Noémie Manent CTIS Operations Workstream Lead Charalampos Drosos CTIS Change Management Officer



Notifications (session II)




Notifications

Trial & Recruitment Periods notifications	Circumstantial events notifications	
Trial Periods	Unexpected events	Serious breaches
Recruitment Periods	Urgent safety measures	Third country inspectorate inspections
These notifications refer to the clinical trial life cycle in each MSC	These notifications are only needed in certain circumstances not foreseen in the protocol and apply to all MSCs	

Events notifications

- Primarily independent of each other
- Can only be submitted after a clinical trial has been decided





2

For notifications on events (not related to the trial and recruitment period), the sponsor user navigates to the **respective notification type** [1] and creates a **new notification draft** [2].

The system assigns a new **business key** [3] and adds this new notification to the list of notifications for that type. **Actions** buttons [4] allow the sponsor user to apply further actions for that notification.

Business key	MSCs	Internal sponsor id		Last modified	Submission	date	Status	Ac	tions	
UE-0106	SE, AT, FR, RO	UE-01		-	06/04/2021		✓ Submitted		Ø Ø O	4
Serious Breach 1										
										+
Business key	Affected countries	MSCs	Internal sponsor id	d I	Last modified	Submission date	Stat	us	Actions	
SB-0107	AT	SE, AT, FR, RO	SB-01		-	06/04/2021 🛦	√ s	ubmitted		
Urgent Safety Meas	sure 1									+
Urgent Safety Meas Business key	MSCs	Internal sponse		Last modifi		Submission date		Status	Actions	+
		Internal sponse USM-01		Last modifi -						+

Publication aspects

- The publication of these event notifications may require an assessment before they are published:
 - ✓ 3rd Country Inspectorate Inspection notifications are published as soon as sponsors submits them
- For the other three types, their publication can be triggered by authority users and only after they perform an *ad hoc* assessment related to the event notification.
- Once authority users perform the *ad hoc* assessment they can trigger the publication of the notification details by attaching the outcome of the assessment to the notification.
- Details of the notification as well as a summary of the assessment outcome performed by authority users are published.



Demo and Q&A session

For questions, go to **www.sli.do** & use event code **#bt23nov**

10 CTIS bitesize talk 23 November 2022 - Notifications (session II)

Classified as public by the European Medicines Agency



We ask for your feedback on this event

A brief **poll is now open** in Slido





Final CTIS events for 2022 – Save the date

Date	Submit your questions in advance!	CTIS event	
24 November	OMS Troubles	Shooting Session for CTIS users	
<u>12 December</u>	CTIS Walk-in clinic		
15 December	CTIS bitesize talk: Annual Safety Report		

<u>Clinical Trials Information System: training and support</u> <u>European Medicines Agency</u>

For satisfaction feedback, Please go to **www.sli.do** & use event code **#bt23nov**



CTIS training environment Survey 4.0

Survey 4.0 has been opened where new potential users of CTIS can express interest to access the CTIS training environment (CTIS Sandbox).

CTIS Sandbox Survey 4.0

For satisfaction feedback, Please go to **www.sli.do** & use event code **#bt23nov**



Q&As on CTR by the European Commission

The European Commission has published a detailed lists of questions and answers on the Clinical Trials Regulation under Chapter V of Eudralex 10:

PAGE CONTENTS

Set of documents applicable to clinical trials authorised under Regulation EU No 536/2014

Set of documents applicable to clinical trials authorised under Directive 2001/20/EC

Latest updates

Documents

Chapter V - Additional documents

- <u>Accelerating clinical trials in the EU (ACT EU) Delivering an EU clinical trials transformation</u> <u>initiative</u> (EN | ••••)
- <u>Questions and Answers Document Regulation (EU) 536/2014 Version 6.2 (September</u> 2022) (EN | •••

Please note that certain Q&As and a section of this document are still being discussed within the expert group on clinical trials and are therefore not yet included. Updated versions of the document will be published progressively.

<u>Q&A on Complex clinical trials (May 2022)</u> (EN I ==)
This document has been developed in close collaboration between the European Medicines

EudraLex - Volume 10 - Clinical trials guidelines - Questions and Answers Document - Regulation (EU) 536/2014 – Version 6.2 (September 2022)



Thank you for attending today's event

Next CTIS bitesize talk

on 15 December

Further information

For the <u>Clinical Trials Newsletter</u> sign up at <u>CT.NewsletterSubscriptions@ema.europa.eu</u>.

For upcoming CTIS events, visit the <u>EMA event page</u>.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands **Telephone** +31 (0)88 781 6000

Follow us on **Magenda Base Series Follow** us on **Series Base Series Follow** us on **Series Follow** us on **Series Base Series Base Series Follow Base Series Base Seri**